SRA in the liver can also block the promoter activity of adipose triglyceride lipase (ATGL) by inhibiting the related effects of transcription factor FoxO1, thereby inhibiting the expression of ATGL to promote liver steatosis and participate in the body's fat metabolism [33]. The gene discussed is PNPLA2; the disease is fatty liver disease.